comparemela.com

Latest Breaking News On - Chong kun dang pharmaceutical corp - Page 1 : comparemela.com

DelveInsight Business Research, LLP: Global Ambulatory Surgical Centers Market is Projected to Boost at a Moderate Growth Rate of ~6% by 2030

Global Infection Prevention and Control Market is Likely to Increase at a Steady Growth Rate of ~6% by 2030

DelveInsight Business Research, LLP: Global Infection Prevention and Control Market is Likely to Increase at a Steady Growth Rate of ~6% by 2030

The surge in the infection prevention and control demand market is due to factors such as the rising occurrence of chronic diseases, escalating rates of surgical procedures necessitating stringent

Chong Kun Dang scores its largest ever $1 3B deal with Novartis for CKD-510

South Korea’s Chong Kun Dang Pharmaceuticals Corp. said that it struck a deal potentially worth $1.3 billion with Swiss pharma giant Novartis AG for its CKD-510 candidate for neurological and cardiovascular diseases, propelling its shares upward 26.11% by market closing of Nov. 6. With the “largest ever” deal in its history, shares of the Seoul-based pharmaceutical (KOSPI:185750) on the Korea Exchange rose by 26.11%, or ₩26,500, closing at ₩128,000 ($98.70).

Chong Kun Dang scores its largest ever $1 3B deal with Novartis for CKD-510

South Korea’s Chong Kun Dang Pharmaceuticals Corp. said that it struck a deal potentially worth $1.3 billion with Swiss pharma giant Novartis AG for its CKD-510 candidate for neurological and cardiovascular diseases, propelling its shares upward 26.11% by market closing of Nov. 6. With the “largest ever” deal in its history, shares of the Seoul-based pharmaceutical (KOSPI:185750) on the Korea Exchange rose by 26.11%, or ₩26,500, closing at ₩128,000 ($98.70).

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.